ANKİLOZAN SPONDİLİTLİ HASTALARDAANTİ-TNF-ALFA TEDAVİ ÖNCESİ VE SONRASI SAKROİLİAK EKLEMLERİN MANYETİK REZONANS İLE GÖRÜNTÜLENMESİ
AMAÇ: Çalışmanın amacı, dirençli AS'li hastalarda, anti-TNF-alfa ilaçların etkinliğini ve güvenirliğini yanısıra, manyetik rezonans (MR) görüntüleme ile tedavi öncesi ve sonrası sakroiliak eklem değişiklerini tespit etmektir.GEREÇ ve YÖNTEM: Modifiye New York tanı kriterlerine göre AS tanısı almış, 27 hasta çalışmaya dahil edildi. Sakroiilitis bulguları, anti-TNF-alfa tedavi öncesi ve sonrası, Gd-MR ile tespit edildi. Sekiz hastaya, 4 haftada bir İnfliximab 4mg/kg i.v. infüzyon verildi. Diğer 19 hastaya ise Etanercept 2x25mg/hafta s.c. verildi. Değerlendirilen klinik ve laboratuvar parametreler; BASDAİ, BASFİ, ağrı (VAS skoru), Schöber testi, göğüs ekspansiyonu, C-reaktif protein (CRP), eritrosit sedimentasyon hızı (ESH).BULGULAR: Hastaların çoğu, anti-TNF-alfa tedavilerine iyi yanıt verdi. 24.haftanın sonunda, takip edilen tüm parametrelerde iyileşme gözlendi. MR görüntüleme çalışmalarında, anti-TNF-alfa tedavi sonrası sadece 3 hastanın sakroiliak eklem inflamasyonunda gerileme gözlendi. SONUÇ: Aktif AS'li hastalarda, 24.hafta sonunda anti-TNF-alfa ilaçları güvenilir ve etkin bulundu. BASDAİ, BASFİ, ağrı skorlarında belirgin düşüş gözlendi. Fakat, sakroiliak eklemin akut inflamatuvar bulgularında, MR görüntüleme ile herhangi bir gerileme tespit edilmedi
Magnetic Resonance Imaging of the Sacroiliac Joints in Ankylosing Spondylitis Before and After Therapy with Anti-Tumor Necrosis Factor Alpha
OBJECTIVE: The goal of this study is to assess the changes in the sacroiliac joints (Sİ) by magnetic resonance imaging (MRI) in a 24-week follow-up period and to determine the efficacy and safety of anti-TNF-α therapies for refractory AS. MATERIAL and METHODS: Twenty-seven patients who met the modified New York criteria for AS were enrolled in this study. Activity of sacroiliitis was determined by Gd-MRI scan before and after anti-TNF-α treatment. Eight patients received infliximab at a dose of 4 mg/kg by intravenous infusion over 2 hours at every 4 week. Other 19 patients were treated with 25mg subcutaneous etanercept twice weekly The total observational period was 24 weeks. The clinical and laboratory variables included: Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), pain on a visual analog scale, Schober's index, chest expansion, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR). RESULTS: Most patients responded well to treatment of anti-TNF-α antagonists. At 24 weeks, there was an improvement in all of the following measures. Imaging studies showed decreased inflammation of the SI joints after 24 weeks of treatment with anti-TNF-α therapies in only 3 patients. CONCLUSION: The anti-TNF-α therapies was safe and effective in treating patients with active AS during 24- week study period. The BASDAI, BASFI, VAS of pain were decreased well. But we could not determine any regression of acute inflammatory changes of the SI joints as depicted by MRI.
___
- 1. Khan MA. Update on spondyloarthropaties. Ann Intern
Med 2002;136:896-907.
- 2. S i e p e r J , B r a u n J . P a t h o g e n e s i s o f
spondylarthropathies: persistan bacterial antigen,
autoimmunity, or both? Arthritis Rheum
1995;38:1547-54.
- 3. Braun J, Sieper J.The sacroiliac joint in the
spondylarthropathies. Curr Opin Rheumatol
1996;7:275-83.
- 4. Braun J, Bollow M, Sieper J. Radiologic diagnosis and
pathology of the spondylarthropathies. Rheum Dis Clin
North Am 1998;24:697-735.
- 5. Dougados M, vam der Linden S, Leirisalo-Repo M,
Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK,
Olivieri I, Dijkmans B, et al. Sulfasalazine in the
treatment of spondyloarthropathy: A randomized,
multicentre, double-blind, placebo-controlled study.
Arthritis Rheum 1995;38:618-27.
- 6. Clegg DO, Reda DJ, Weisman MH, Blackburn WD,
Cush JJ, Cannon GW, Mahowald ML, Schumacher HR
Jr, Taylor T, Budiman-Mak E, Cohen MR, Vasey FB,
Luggen ME, Mejias E, Silverman SL, Makkena R,
Alepa FP, Buxbaum J, Haakenson CM, Ward RH,
Manaster BJ, Anderson RJ, Ward JR, Henderson WG.
Comparison of sulphasalazine and placebo in the
treatment of ankylosing spondylitis. Arthritis Rheum
1996;39:2004-12.
- 7. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F,
Herbst H, Eggens U, Distler A, Sieper J. Use of
immunohistologic and in situ hybridization techniques
in the examination of sacroiliac joint biopsy specimens
from patients with ankylosing spondylitis. Arthritis
Rheum 1995;38:499-505.
- 8. Van den Bosch F, Kruithof E, Baeten D, De Keyser F,
Mielants H, Veys EM. Effects of loading dose regiment
of three infusions of chimeric monoclonal antibody to
tumor ne c rosis f a c tor α (infliximab) in
spondyloarthropathy: an open pilot study. Ann Rheum
Dis 2000;59:428-33.
- 9. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J,
Reddig J, Thriene W, Sieper J, Braun J. Successful
treatment of active ankylosing spondylitis with the
anti-tumor necrosis factor α monoclonal antibody
infliximab. Arthritis Rheum 2000;43:1346-52.
- 10. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen
H, Grassnickel L, et al. Six-month results of a doubleblind,
placebo-controlled trial of etanercept treatment
in patients with active ankylosing spondylitis. Arthritis
Rheum 2003;48:1667–75.
- 11. Oostveen JC, van de Laar MA. Magnetic resonance
imaging in rheumatic disorders of the spine and SI
joints. Semin Arthritis Rheum 2000;30:52-69.
- 12. Bollow M, Brandt J, Haberle HJ, Sieper S, Hamm B.
Use of magnetic resonance imaging to detect spinal
i n f l a m m a t i o n i n s p o n d y l o a r t h r o p a t h y
patients(abstract). Arthritis Rheum 1998;41Suppl
9:S358.
- 13. Braun J, Bollow M, Eggens U, König H, Distler A,
Sieper J. Use of dynamic magnetic resonance imaging
with fast imaging in the detection of early and advanced
sacroiliitis in spondyloarthropathy patients. Arthritis
Rheum 1994;37:1039-45.
- 14. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper
J, Braun J. Magnetic resonance imaging of the spine
and the sacroiliac joints in ankylosing spondylitis and
undifferentiated spondyloarthritis during treatment
with etanercept Ann Rheum Dis 2005;64;1305-1310
- 15. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit
M, Listing J, Bollow M, Sieper J, van der Heijde D.
Magnetic resonance imaging examinations of the spine
in patients with ankylosing spondylitis, before and after
successful therapy with infliximab. Arthritis &
Rheumatism Vol. 48, No. 4, April 2003, pp 1126–1136.
- 16. Jee WH, McCauley TR, Lee SH, Kima SH, Ima SA,
Had KY. Sacroiliitis in patients with ankylosing
spondylitis: association of MR findings with disease
a c t i v i t y. M a g n e t i c r e s o n a n c e i m a g i n g
2004:22;245–250.
- 17. Bollow M, Fischer T, Reisshauer H, Backhaus M,
Sieper J, Hamm B, et al. Quantitative analyses of
sacroiliac biopsies in spondylarthropathies: T cells and
macrophages predominate in early and active
sacroiliitis—cellularity correlates with the degree of
enhancement detected by magnetic resonance imaging.
Ann Rheum Dis 2000;59:135–40.
- 18. Bollow M, Enzweiler C, Taupitz, Golder W, Hamm B,
Sieper J, et al. Use of contrast enhanced magnetic
resonance imaging to detect spinal inflammation in
patients with spondyloarthritides. Clin Exp Rheumatol
2002;20 Suppl 28:167-74.